|
Video: What is a Stock Split?
|
|
Biora Therapeutics is a biotechnology company. Co. supports patients and physicians during patients' life decisions with its suite of molecular tests, including: Innatal Prenatal Screen, which is a noninvasive prenatal test provided to women early in pregnancy to screen for risk of fetal chromosomal conditions, such as Down syndrome and sex chromosome disorders; and Resura Prenatal Test for Monogenic Disease, which is a test for monogenic diseases. Co.'s precision medicine development pipeline includes Recoverable Sampling System, which is an ingestible capsule platform designed to enable the collection, preservation, and analysis of samples. According to our PROG split history records, PROG has had 0 splits. | |
|
PROG (PROG) has 0 splits in our PROG split history database.
Looking at the PROG split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into PROG shares, starting with a $10,000 purchase of PROG, presented on a split-history-adjusted basis factoring in the complete PROG split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/22/2020 |
|
End date: |
05/06/2022 |
|
Start price/share: |
$11.97 |
|
End price/share: |
$0.89 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-92.61% |
|
Average Annual Total Return: |
-75.14% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$739.34 |
|
Years: |
1.87 |
|
|
|
|
|